ArticleClinical case reports2026
Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is an advanced disease with poor prognosis and limited treatment options. Conversion therapy integrating locoregional and systemic modalities may expand surgical eligibility, but achieving pathological complete response (pCR) remains rare. We report an adult patient with chronic hepatitis B and China Liver Cancer Staging (CNLC) stage IIIb HCC with extensive PVTT. Baseline alpha-fetoprotein (AFP) was 84,246 μg/L and des-γ-carboxy prothrombin (DCP) 3605 mAU/mL. After three cycles of transarterial chemoembolization (TACE) plus hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and sintilimab, the tumor markedly regressed, PVTT was downstaged from type III to type II, and tumor markers declined (AFP 115 μg/L, DCP 47.1 mAU/mL). Thirty-two days after cessation of systemic therapy, the patient underwent left hemihepatectomy with portal vein thrombectomy, and histopathology confirmed pCR with complete tumor necrosis and no viable cells in the liver or thrombus. Postoperative follow-up imaging and serial tumor markers demonstrated no recurrence, with AFP normalizing to 5.6 μg/L at 1 month and remaining within normal range during 9 months of follow-up after discontinuation of adjuvant therapy. The patient recovered well and was discharged 2 weeks postoperatively. This case highlights the potential of multimodal conversion therapy combining TACE, HAIC, targeted therapy, and immunotherapy to induce durable pCR in advanced HCC with PVTT, offering a promising strategy to improve outcomes in this highly challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.